NVAX
NovavaxยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
NVAX Profile
Novavax, Inc.
A world's leading COVID-19 vaccine development company
700 Quince Orchard Road, Gaithersburg, Maryland 20878
--
Novavax, Inc., incorporated in 1987 under the laws of the State of Delaware, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The company's vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology including virus-like particles (VLP) and protein nanoparticle vaccine candidates. The company's vaccine candidates are genetically engineered three-dimensional nanostructures that contain immunologically important proteins. The company's vaccine product pipeline targets a variety of infectious diseases, and drug candidates are currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, and pandemic influenza. In addition, the company's joint venture in India, CPL Biologics Private Limited (CPLB), is actively developing a number of vaccine candidates that have been genetically engineered by Novavax.
